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Available online 25 September 2016Background: Provisional stenting (PS) is effective for great majority of patients with coronary bifurcation lesions.
Double kissing (DK) crush approach demonstrated signiﬁcant reduction of target lesion revascularization (TLR)
for patients with more complex bifurcation lesion when compared with PS. Furthermore, DK crush technique
was associated with lower rate of composite major adverse cardiac event (MACE), revascularization and stent
thrombosis (ST) for patients with unprotected distal left main coronary artery bifurcation lesions (ULMb), com-
pared to culotte stenting approach. The DKCRUSH V trial is designed to elucidate the beneﬁts of DK crush over PS
in patients with ULMb.
Study design: DKCRUSH V is a randomized, prospective, multinational clinical trial designed to evaluate the efﬁ-
cacy and safety of DK crush over PS for patientswith ULMb. SubjectswithMedina 1,1,1 or 0,1,1 ULMbwill be ran-
domized in a 1:1 fashion to PS or DK crush. The primary endpoint is target lesion failure (TLF) including targetKeywords:
Coronary artery
Provisional side branch stenting
Double-kissing crush
Left main bifurcation lesionsjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing 210006, Jiangsu, China.
. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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point, and target vessel revascularization. The safety objective is the ST. Recruitment began in January 2012
andwas completed inDecember 2015; 484 patients were randomized. The trial will continue until at least 56 ad-
judicated primary endpoints occur.
Conclusions: The DKCRUSH V study is investigating if DK crush approach versus PS will reduce the incidence of
TLF in patients with symptomatic ULMb.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Percutaneous coronary intervention (PCI) using DES dramatically
reduces the requirement of revascularization for patients with obstruc-
tive coronary artery stenosis, as compared to bare metal stents [1,2].
However, stenting coronary artery bifurcation lesions is technically
challenging and associated with less acceptable results mainly due to
higher rate of in-stent restenosis (ISR) particularly at ostial side branch
(SB). Furthermore, previous studies demonstrated that systematical
two stents techniques did not put any advantages over provisional
stenting (PS) approach, and PS was effective for great majority of bi-
furcation lesions [3–6]. When NORDIC stent technique study [7]
showed the reduced rate of ISR by culotte technique compared to
classical crush stenting, our group reported the beneﬁts by double
kissing (DK) crush over either PS [8] for overall of bifurcated stenosis
or over culotte stenting [9] for left main distal bifurcation lesions
(ULMb). Left main coronary artery is featured by a larger SB, de-
creased left ventricular function, more frequent multi-vessel disease
and chronic total occlusion (CTO) in right coronary artery (RCA).
However, there is a lack of data showing the advantage of PS versus
DK crush stenting for ULMb.
1. Provisional stenting for ULMb
J-cypher Registry using cypher stent [10] showed a 7.6% TLR for dis-
tal left main disease (rather than ULMb), similarly to the results by
Palmerini et al. [11]. French Registry [12] is divided into three arms,
the ﬁrst TAXUS 2004 registry had a 5.9% TLR, the FRIEND and LEMAX
using sirolimus-eluting stent had 2.7% and 2.3% TLR, respectively. How-
ever, these three registry studies did not provide stronger evidences be-
cause of no consistent stenting techniques and lesions classiﬁcations.
Price et al. [13] reported a 38% TLR in a smaller study (n= 50) for distal
left main disease. The shortcomings of these studies are the lack of non-
randomization, lack of using propensity score to compare patients in
pair, and all distal lesions (bifurcation and non-bifurcation lesions)
were included.
2. DK crush stenting for ULMb
Even the fact that PS has been effective for great majority of entire
coronary bifurcation lesions, lesions' complexity has been thought to in-
ﬂuence the clinical outcomeswhen previous studies [3–6] are analyzed.
CACTUS [5], BBK [6], BBC ONE [4] and NORDIC Bifurcation Study [3] tri-
als compared different two-stent techniques versus PS, and did not re-
port beneﬁts by two-stent techniques over PS. However, a wide
discrepancy in study design existed among these studies. For example,
SB lesions length in NORDIC study [3] was only 2.8mm in PS group, sig-
niﬁcantly different to 10.3mm in two-stent group. Also, baseline SB and
main vessel (MV) diameter stenosis was around 40%, tremendously less
severe than other studies [8–10]. Our DKCRUSH I [14], DKCRUSH II [8]
and DKCRUSH III [9] trials showed the baseline SB lesion length longer
than 10 mm, with more complex lesions or more patients at high-risk
(MI, chronic total occlusion, multi-vessel disease) included, compared
to others [3–6].
Recently, we have reported a new stratiﬁcation for classifying the bi-
furcation lesions' complexity, DEFINITION criteria [15], which demon-
strated that PS was associated with lower rate of composite major
adverse cardiac event (MACE) for overall bifurcations or simplebifurcated lesions. In contrast, two-stent technique reduced in-hospital
MACE and 1-year cardiac death for complex bifurcation lesions when
compared with PS. As patients with ULMb have more complex lesions,
and complete revascularization could not be achieved for most of
these patients, the comparison of treatment effects by PS or two-stent
techniques is critical.
Although previous studies did not show any difference in MACE be-
tween two-stent techniques, NORDIC stent technique study [7] report-
ed less frequent in-stent restenosis (ISR) at ostial SB by culotte over
classical crush approach. Furthermore, our DKCRUSH III study [9], a
ﬁrst RCT comparing DK crush with culotte for ULMb, revealed that pa-
tients were beneﬁted from DK crush, compared to culotte stenting
through 3-year follow-up [16]. Taking together, insight analysis from
subgroup of patients with ULMb in our DKCRUSH I [14] and DKCRUSH
II [8] studies, a ﬁve-times reduction in TLR was achieved by DK crush
(3.9%), compared to 20.7% by provisional T stenting, a ﬁnding was sup-
ported by the only one RCT, DKCRUSH III trial [9], for ULMb. As a result,
the signiﬁcant improvement of clinical outcomes by DK crush over PS
for patients with ULMb is critically to be tested in a RCT, which will si-
multaneously elucidate the reasonwhy PS cannotwin in the population
with ULMb.
3. Study design and population
DKCRUSH V is an international, multicenter, randomized, endpoint-
driven study to evaluate the beneﬁts by DK crush compared with PS for
patients with ULMb. The study is shown in Figure (Chictr.org, no
ChiCTR-TRC-11001213).
The inclusion criteria for DKCRUSH V are designed to enroll a repre-
sentative sample of subjects with ULMb. Study patients must be 18–
80 years of age with objective evidences of ischemia, deﬁned by 2 of
the following: (1) Medina 1,1,1 and 0,1,1, and (2) both ostial left anteri-
or descending artery (LAD) and left circumﬂex (LCX) diameter stenosis
≥50% by visual estimation.
Key exclusion criteria included Severe calciﬁcation needing rotation-
al atherectomy, restenotic lesions, and acute myocardial infarction
b24 h. All patientsmust providewritten informed consent for participa-
tion. A complete listing of the inclusion/exclusion criteria is provided in
Table 1.
DKCRUSHV patients were being randomized in a 1:1 ratio to receive
either PS or DK crush stenting technique. Everolimus eluting stents,
biolimus eluting stents, or sirolimus eluting stents will be implanted
during the procedures duo to the discretion of the operators. Recruit-
ment began in January 2012 and was completed in December 2015,
and 484 patients were randomized. Two patients were excluded due
to double enrolled and randomized (i.e., same patient enrolled and ran-
domized at 2 separate sites), therefore, the total number of randomized
subjects was 482. The baseline characteristics of patients enrolled in
DKCRUSH V are shown in Table 2. There were 4 patients suffered previ-
ous Aorta-RCA CABG with occluded saphenous graft. Randomized sub-
jects are being followed for all clinical endpoints and serious adverse
events (SAEs) until the end of the study, with the primary and several
secondary endpoints events conﬁrmed by Independent Committee.
The trial will continue until January 2017.
The study is being performed in accordance with ethical principles
consistent with the Declaration of Helsinki, International Conference
Table 1
Inclusion and exclusion criteria.
Inclusion
Patient must be at least ≥18, ≤80 years of age.
Lesions are eligible for percutaneous coronary intervention (PCI).
Patient has stable/unstable angina or myocardial infarction (MI).
ULMb (Medina 0,1,1/1,1,1) with/without left main ostial/shaft lesions.
Downstream lesions in LAD or LCX could be covered by two stents.
ULMb with chronic total occlusion (CTO) lesion in LAD, or LCX or RCA after
recanalization.
Diameter stenosis in LAD/LM and LCX ≥ 50% by visual estimation.
Exclusion
Patient with MI b 24-h from the onset of chest pain to admission).
Patient was allergic to the study stent or protocol-required concomitant
medications.
Patient is intolerable to dual anti-platelet therapy.
Patient has any other serious medical illness that may reduce life expectancy to
b12 months.
Patient is a woman who is pregnant or nursing.
Patient has a planned procedure that may cause non-compliance with the
protocol or confound data interpretation.
Patient is participating in another clinical trial that has not reached its primary
endpoint within 24 months after the index procedure.
CTO lesion in either LAD, or LCX or RCA not re-canalized.
Severe calciﬁcation needing rotational atherectomy.
Distal left main coronary restenosis.
Table 2
Baseline characteristics of patients included in DKCRUSH V at study entry.
All patients (N = 482)a
Age, y 64.44 ± 9.6
Male sex 387(80.3)
Medical history
Hypertension 322(66.8)
Hyperlipidemia 231(47.9)
Diabetes mellitus 127(26.3)
Acute myocardial infarction b 24 h 53(11.0)
Previous PCI 58(12.0)
Previous CABG 4(0.8)
Medina classiﬁcation
Medinal 1,1,1 406(84.2)
Medina 0,1,1 76(15.8)
Renal dysfunction 20(4.1)
Data presented as number (percentage), unless otherwise indicated.
PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft.
a N represented ﬁnal total number of patients, not randomizations. Two patients were
determined to be double enrolled.
Figure. DKCRUSH V study ﬂowchart.
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ulatory requirements. The ﬁnal study protocol and informed consent
have been reviewed and approved by the corresponding health author-
ities and ethics boards/institutional review boards for all participatingstudy sites. Enrolled patients gave written informed consent for partic-
ipation in the trial.
4. Study protocol and follow-up procedure
4.1. Periprocedural medication
A loading dose of aspirin (300 mg) and clopidogrel (300 mg) is rec-
ommended for all patients if not used before admission, at least 6 h be-
fore PCI procedure.
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contemporary guidelines and local practice. Per-procedural medical
treatment in all patients include: unfractioned heparin (100-120 U/kg
i.v.), low molecular heparin (0.7 mg/kg s.c.) or bivalirudin.
Following PCI, lifelong aspirin in a dose of 100 mg/d will be pre-
scribed. Duration of clopidogrel treatment is 12-month (75 mg/d). Life-
long clopidogrel treatment may be used in individual patients at the
discretion of the operator. A loading dose of aspirin (300 mg) and
clopidogrel (300mg) is recommended for all patients, at least 6 h before
PCI procedure.
4.2. Biomarker assessment
Creatine Kinase Myocardial-Band Isoenzyme and TNT/TNI will be
assessed before the procedure and 6–9(optional) and 12–24 h after
the index procedure.
4.3. Angiography assessment
The index angiograms will be assessed by the QCA-laboratories at
China Cardiovascular Research Fundation (CCRF, Beijing, China). All
the lesions will be described and classiﬁed by SYNTAX [12], and NERS
[17] scores.
Basic angiograms for all lesions should consist of at least injections
after intracoronary injection of 100-200 μg nitroglycerin (documented
on angiogram). Bifurcation-view must be gained for all patients; there
should be an angulation difference between the two baseline angio-
grams of at least 30°. The diagnostic/guiding catheter should bewell vis-
ible, near the center of the angiogram and ﬁlled with dye. The index
lesions should be well visible, near the center of the angiogram and
shown without foreshorting. Between the pre- and post-angiograms
all balloon inﬂations and stent implantations should be documented
by short cine-runs.
5. Intravascular ultrasound analysis
After intra-coronary administration of nitroglycerin(100–200 μg),
the imaging catheter was advanced by at least 10 mmbeyond the distal
edge of the stent under ﬂuoroscopic guidance, and IVUS images were
obtained with automated pullback (0.5 mm/s) using a commercially
available imaging system with a 40-MHz mechanical transducer (Bos-
ton Scientiﬁc Corporation, Natick, MA, USA). The 12 images were re-
corded on a DVD for subsequent off-line analysis. The IVUS images
were analyzed by two technicians who were blind to the study design.
The inter- and intra-observer variability was under 5%, determined
using the Kappa test. All IVUS analysis was performed using dedicated
software (EchoPlaque, IndecSystems, Mountainview, CA, USA). IVUS
measurements included the minimum stent cross-sectional area
(MSA), the minimum lumen area (MLA), the stent expansion index,Table 3
Secondary endpoints.
Combined endpoint of all-cause death, MI, TVR at 1-year
Individual endpoints of all-cause death, cardiac death, MI, TLR, TVR at 1-year
Deﬁnite and probable stent thrombosis
NYHA functional class
Angina CCS class
Braunwald class
ISR
Net gain of lumen diameter
Procedure related biomarker release
Stroke
Outer diameter of guiding catheter
Devices consumed during indexed procedure
Contrast volume
Procedural time
X-ray exposure time
X-ray dose, DAP-total, DAP-record, DAP-ﬂuorothe stent symmetry index and stent opposition at the minimum stent
area. The stent expansion index was deﬁned as the ratio of the mini-
mum stent cross-sectional area (CSA) divided by the distal reference
lumen area. The stent symmetry index was deﬁned as the ratio of the
minimum stent diameter divided by the maximum stent diameter.
The incomplete crush was deﬁned as the incomplete apposition of the
SB or the MV stent struts against the MV wall proximal to the carina.
The late luminal loss was deﬁned as the difference between the lumen
CSA post-procedure and at follow-up. The chronic stent recoil was de-
ﬁned as the difference between the minimal stent CSA post-procedure
and at follow-up. Neointimal hyperplasia (NIH) was deﬁned as the dif-
ference between the stent CSA and the lumen CSA at follow-up. The
Core Lab for QCA and IVUS analysis is, Nanjing, China.
6. Randomization procedure
The patientswill be randomized after angiography to either DKor PS
group. The randomization serial number for patients will be performed
by Interactive Web Randomization System (IWRS). The randomization
serial number for each participating center will be undergone by the
same system.
6.1. Patient follow-up
All patients will be seen at the outpatient clinic of the participating
centers after 1-, 6-, and12-month. The outpatient visitmay be substitut-
ed with a telephone contact and subsequent investigational documen-
tation forms. Angiographic follow-up would be undergone at 13-
month after index procedure, and would be encouraged for 80% of all
patients, with IVUS & FFR for 50% of all patients. Earlier re-angiography
will not be suggested unless clinically indicated earlier.
7. Study endpoints
The primary endpoint in this trial is the composite of cardiac death,
target vessel MI and target lesion revascularization at 1-year after
indexed procedure. The major secondary endpoints include stent
thrombosis (safety endpoint), in-stent restenosis, target vessel revascu-
larization (TVR), MI, and each individual component of the primary
endpoint (Table 2). Deﬁnition of study endpoints are described in Ap-
pendix A.
All endpoints are site-reported in an electronic Web-based capture
system with additional submission of supporting medical documents
where applicable. Adjudication for each event is performed according
to deﬁnitions in the DKCRUSH V Clinical Endpoints Charter by 3 mem-
bers in Independent Committee (see Organization).
8. Statistical considerations
The primary efﬁcacy variable is time from randomization to ﬁrst oc-
currence of any event from the primary composite of cardiac death, tar-
get-vessel MI and TLR. The analysis of all efﬁcacy variables will be based
on the intention-to-treatment principle using the Cox-proportional
hazards model with a factor for treatment group. The hazard ratio for
PS versus DK crush with 95% CIs will be presented. To address the
issue of multiple testing, the conﬁrmatory analysis will comprise a hier-
archical test sequence with the primary efﬁcacy variable followed by
the secondary efﬁcacy variables in the order listed in Table 3. Efﬁcacy
analysis will be conducted on an intention-to-treat basis among all sub-
jects randomized. The safety evaluationwill include all subjects who re-
ceived either PS or DK crush treatment and within 7 days after stenting
procedures. Subgroup analysis will be performed to evaluate variation
of treatment effects, as well as a test of interaction with treatment for
each subgroup variable. The P values of the subgroup analyses and inter-
action tests will not be adjusted for multiple comparisons because the
tests are exploratory and will be interpreted descriptively. Subgroup
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Subgroup analyses will be based on the set of baseline variables (online
Appendix Supplementary Table 1).
Trial sample size estimation required estimates of TLF rates in sub-
jects with ULMb. To detect a true hazard ratio of o.85, randomization
of approximately 484 patients with ULMb was expected to yield a pri-
mary endpoint event of 14% in provisional stenting group and 6% in
DK group, providing 80% power. An independent data monitoring com-
mittee (DMC) has responsibility for monitoring safety during the trial
and will perform 3 interim analyses of efﬁcacy when approximately
half of the projected primary endpoints have been accrued and adjudi-
cated. At its discretion, the independent DMC may perform additional
efﬁcacy looks. An alpha spending function will govern interim and
ﬁnal statistical testing to control the overall type I error of 5%.
9. Study organization
All centers with experience and interest in left main stenting tech-
niques and with a potential of randomizing N 15 patients in the study
during a 12-month period can participate in the study.
Rules for membership of the steering committee: 1) Writing of pro-
tocol and advisory activity concerning the study protocol; 2) Inclusion
of N25 patients in the study; one membership; 3) Inclusion of N45 pa-
tients; two membership. The steering committee members will be se-
lected on basis of participation in the study.
There will be a country coordinating principal investigator (PI) for
each participating country and one PI for each center. The PIs will be re-
sponsible for the study in the respective countries. Further, they will be
key members of the steering committee of the study (steering commit-
tee nucleus), and in charge of the study. The PIs will take care of the
study at center level and will be members of the steering committee
in actively including centers.
All steering committeememberswill have full access to the database
and will participate in the interpretation of data.
9.1. Independent endpoint committee
Primary and secondary endpoints will be assessed by an indepen-
dent endpoint committee (IEC)—Treatment Effects Monitoring Com-
mittee (TEMC) and Advisory-review Committee. The endpoint
committee will consist of experienced cardiologists, trialists, statisti-
cians, and interventionalists.
10. Discussion
Despite the extensive use of PS for coronary bifurcation lesions, the
evidence base for therapies aimed at improving clinical outcomes in pa-
tients with ULMb is limited. The FRENCH and LEMAX registry for the
ﬁrst time reported the incidence of TLF from a large population of pa-
tients with unprotected left main disease. In that two-arm registry
study, 75.9% of patients had distal left main disease, of them PS was
used in 91.1% of lesions with additional SB stent required in 22% of pa-
tients. Notably, Medina 1,1,1 (46.8%) and 0,1,1 (3.2%) only accounted
for 50% of overall patients. As such, we postulated that the rate of TLF
would be N11.9% if all lesions were classiﬁed by Medina 1,1,1 or 0,1,1.
On the other hand, from the ﬁrst RCT comparing DK crush vs culotte
stenting for ULMb deﬁned by Medina 1,1,1 and 0,1,1, we found a dra-
matic reduction of composite MACE rate by DK crush, with TLF b6%.
Therefore, DKCRU V trial will provide evidence to address the role of
two-stent technique, particularly in DK crush, for true ULMb lesions.
10.1. Study population
Patients with unprotected left main disease are at their risk of CV
events and CABG is recommended to be “gold-standard” for such partic-
ular patients. When we are waiting for the results by EXCEL studycomparing DES with CABG for patients with left main disease and SYN-
TAX score b 33, stenting approach for true ULMb is still technically de-
manding. To address the role of DK crush in ULMb, DKCRUSH V study
includes the real true ULMb (Medina 1,1,1 and Medina 0,1,1). When
we considered a large trial aimed at ULMb patients, there were several
important design consideration in DKCRUH V, including MI N 24 h,
CTO lesions in either LAD or LCX or RCA after successful percutaneously
recanalization, calciﬁcation without requirement of atherectomy. In ad-
dition, one of the challenges in DKCRUSH V was that most patients
would had have high SYNTAX score (data not included in the Tables).10.2. Selection of participating centers
Given the fact that DK crush consists of 5 steps including stenting SB,
balloon crush, ﬁrst kissing, stenting MV, ﬁnal kissing, all participating
centers should have yearly PCI number N 500 and the primary operator
in each center should have yearly number of stenting ULMb N 50. Before
the study, each qualiﬁed center should provide 3 stenting cases of ULMb
for PS and DK crush, respectively. If stenting techniques did not comply
with protocol by steering committee, training on additional 3 cases was
performed.10.3. Management during the study
The study will be monitored according to the GCP rules by indepen-
dent professionals. During the study period, monitor will have regular
contact to the participating departments to ensure that the trial is con-
ducted in compliance with the protocol, GCP and applicable regulatory
requirements. The monitor will ensure that the used products are all
right and will review source documents for veriﬁcation of consistency
with the data recorded in the CRF's. The monitors will also provide in-
formation and support to the investigators(s).
Investigators and other responsible personnelmust be available dur-
ing themonitoring visits, audits and inspections and should devote suf-
ﬁcient time to these processes.
The investigator should provide a CV or equivalent documentation
of suitability to be responsible for the trial. All investigators and other
responsible personnel should be listed together with their function in
the trial on the signature list.
The investigator(s)/Institution(s) will permit study-related moni-
toring, audits, IEC review and regulatory inspection(s), providing direct
access to source/hospital records. The investigator veriﬁes that each pa-
tient has consented in writing to direct access to the original source
data/hospital records by the use of written information and signed in-
formed consent.
During themonitoring, the data recorded in the e-CRFs by the inves-
tigator will be controlled for consistency with the source data/hospital
records by the studymonitor (source data veriﬁcation). Any discrepan-
cies of data will be documented and explained in the monitoring
reports.
The progress of the study will be checked on a weekly basis by the
steering committee. They will receive and evaluate data on inclusion
rate and the primary endpoint event rate.
The steering committee will receive data by e-mail and answer by e-
mail with copy to all members. The studywill bemonitored by the coor-
dinating investigators based on input from independent professionals.10.4. Treatment of patients with ISR
The options of treatment for patients with ISR were left at
physician's discretion. However, re-PCI with drug-eluting balloon, dif-
ferent DES and kissing balloon inﬂation was recommended for focal
ISR. Otherwise, CABG was recommended for patients with multiple or
diffuse ISR [18,19].
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The DKCRUSHV trial is investigatingwhether DK crush stenting ver-
sus PS reduces TLF in patients with true ULMb.
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